Sharechat Logo

Greenfern Industries Limited (NZX: GFI) Greenfern has commenced distributing GMP medications in Aus

Tuesday 9th November 2021

Text too small?

Greenfern has commenced distributing GMP medications in Australia with promising early uptake from prescribers.

Greenfern Industries has begun to make significant inroads into the Australian medicinal cannabis market, signing a distribution agreement with Cannvalate Pty Ltd.

Greenfern’s wholly-owned Australian subsidiary GFI Pharma Pty Ltd, and GFI’s New Zealand senior management team have been developing a strategic relationship with Cannvalate to develop awareness of the GFI Pharma brand across the 3000+ doctors and 600+ pharmacies in their network. Cannvalate has extensive business interests in the medical cannabis sector in Australia. Interests include the largest network of prescribing doctors and dispensing pharmacies. Australia is one of the world's largest cannabis markets outside of North America.

Greenfern managing director Dan Casey said GFI Pharma has two Australian pharmaceutical GMP (good manufacturing practice) medications that have been manufactured in Australia and are now available to Australian patients. Greenfern will also look to offer the GMP medications to New Zealand once local approvals have been obtained.

GFI is leveraging Cannvalate’s extensive network to collate real-world data from patients. This activity is part of a wider scope of work being led by GFI Pharma to research and develop the safety and efficacy of cannabinoid medications.

There has been significant and immediate uptake on the GFI Pharma range and over $100,000 of medication has already been sold into distribution channels.

The relationship between Greenfern and Cannvalate extends to Epsilon Healthcare and The Valens Company, both of which are involved in the manufacture of GFI Pharma’s two medications. Epsilon recently announced it would make its Queensland-based production facility available to Canadian medicinal cannabis manufacturer The Valens Company under a long-term partnership.

Background

Greenfern Industries listed on NZX on the 21st of October 2021. The market has strongly supported the new listing.

Greenfern’s main business is the production and distribution of medicines and food from cannabis and hemp plants.

The company aims to be a leading New Zealand product and wholesale distributor of medicinal cannabis products as well as hemp-based health and beauty products, and hemp-based foods.

For further information, please contact:

Dan Casey

Managing Director, Greenfern Industries

Ph: 0274 202 476 Email: dan@gfi.nz

Please see the link below for details

20211109 Greenfern signs a significant medicinal cannabis agreement in Australia

Source: Greenfern Industries Limited



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

ArborGen Holdings Limited (NZX: ARB) Updates Market on FY22 Guidance
My Food Bag Group Limited (NZX: MFB) Q3 FY22 Trading Update
ikeGPS Group Limited (NZX: IKE) signs $0.9m deal with tier-1 electric utility
Tower Limited (NZX: TWR) Update on Tonga Volcanic Eruption and Tsunami Event
21st January 2022 Morning Report
Trade Window Holdings Limited (NZX: TWL) TradeWindow and Mastercard teams up
Genesis Energy Limited (NZX: GNE) FY22 Q2 Performance Report
Seeka Limited (NZX: SEK) Seeka announces dividend of 13 cents per share
20th January 2022 Morning Report
Z Energy Limited (NZX: ZEL) Q3FY33 Operating Data